先声药业(2096.HK):多项数据公布于ASCO大会 产品销售及出海潜力提升

交银国际
04 Jun

基于公司近期在国际学术会议上公布了苏维西塔单抗、口服SERD、多款ADC等潜在重磅产品的优异数据,我们认为将带动更多出海交易、提升产品上市后的医患认可度、加速公司创新平台价值验证。上调目标价至14.3 港元。ASCO 2025 大会公布多项重要临床数据:ASCO 2025 大会上,公司肿瘤管线共有18 项研究获展示,涵盖苏维西塔单抗、SIM0270(口服SERD)、科赛拉等重点品种。我们建议重点...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10